









市场行情
/
股票
/
nasdaq-nuvb
/

Nuvation Bio Inc

NUVB

8.965USD

+0.025+0.28%

收盘 12/31, 16:00（美东）报价延迟15分钟

3.07B总市值

亏损市盈率 TTM



Nuvation Bio Inc

8.965

+0.025+0.28%

概览公司财务分析

概览

公司

财务

分析

关于 Nuvation Bio Inc 公司

Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.

Nuvation Bio Inc简介



公司代码NUVB

公司名称Nuvation Bio Inc

上市日期Jul 01, 2020

CEOHung (David T)

员工数量220

证券类型Ordinary Share

年结日Jul 01

公司地址1500 Broadway

城市NEW YORK

上市交易所NASDAQ OMX NASDAQ Basic NYSE

国家United States of America

邮编10036

电话13322086102

网址https://www.nuvationbio.com/

公司代码NUVB

上市日期Jul 01, 2020

CEOHung (David T)

Nuvation Bio Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. David T. Hung, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

60.28M

+0.84%

Mr. Kim D. Blickenstaff

Independent Director

172.19K

Dr. Robert Mashal, M.D.

Independent Director

100.00K

Ms. Colleen Sjogren

Chief Commercial Officer

78.00K

+178.57%

Ms. Kerry A. Wentworth

Chief Regulatory Officer

50.00K

Mr. Moses Makunje, CPA

Principal Accounting Officer, Vice President - Finance

10.61K

Ms. Stacy Markel

Chief People Officer

10.00K

Mr. Philippe Sauvage

Chief Financial Officer and Principal Financial Officer

7.30K

Mr. Robert B. (Rob) Bazemore, Jr.

Lead Independent Director

5.00K

Mr. Joe Rayne

Investor Relations

名称

名称/职务

职务

持股

持股变动

Dr. David T. Hung, M.D.

Chairman of the Board, President, Chief Executive Officer, Founder

60.28M

+0.84%

Mr. Kim D. Blickenstaff

Independent Director

172.19K

Dr. Robert Mashal, M.D.

Independent Director

100.00K

Ms. Colleen Sjogren

Chief Commercial Officer

78.00K

+178.57%

Ms. Kerry A. Wentworth

Chief Regulatory Officer

50.00K

Mr. Moses Makunje, CPA

Principal Accounting Officer, Vice President - Finance

10.61K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Hung (David T)

17.63%

Fidelity Management & Research Company LLC

14.64%

Decheng Capital LLC

7.59%

BlackRock Institutional Trust Company, N.A.

5.84%

The Vanguard Group, Inc.

4.50%

其他

49.78%

持股股东

占比

Hung (David T)

17.63%

Fidelity Management & Research Company LLC

14.64%

Decheng Capital LLC

7.59%

BlackRock Institutional Trust Company, N.A.

5.84%

The Vanguard Group, Inc.

4.50%

其他

49.78%

股东类型

持股股东

占比

Investment Advisor

31.19%

Individual Investor

19.21%

Hedge Fund

11.09%

Venture Capital

10.58%

Investment Advisor/Hedge Fund

10.37%

Research Firm

1.68%

Private Equity

0.42%

Bank and Trust

0.23%

Pension Fund

0.20%

其他

15.03%

机构持股



更新时间: 1 小时前

报告期

机构数

持股数

持股占比

持股变动

2025Q4

368

224.86M

65.78%

-37.90M

2025Q3

355

228.75M

66.72%

-24.74M

2025Q2

346

279.19M

82.03%

-27.71M

2025Q1

346

276.31M

81.30%

-31.14M

2024Q4

336

290.52M

86.58%

+4.56M

2024Q3

324

278.55M

83.07%

+36.83M

2024Q2

323

221.78M

89.68%

-2.09M

2024Q1

305

194.38M

89.06%

-41.04M

2023Q4

290

194.02M

89.00%

-35.90M

2023Q3

285

196.95M

90.37%

-25.21M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Hung (David T)

60.28M

17.61%

+500.00K

+0.84%

Jun 16, 2025

Fidelity Management & Research Company LLC

50.47M

14.75%

+440.09K

+0.88%

Jun 30, 2025

Decheng Capital LLC

25.95M

7.58%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

20.99M

6.13%

+5.12M

+32.27%

Jun 30, 2025

The Vanguard Group, Inc.

15.84M

4.63%

+505.23K

+3.29%

Jun 30, 2025

Laurion Capital Management LP

10.24M

2.99%

+369.63K

+3.74%

Jun 30, 2025

Omega Fund Management, LLC

11.04M

3.23%

-2.03M

-15.53%

Jun 30, 2025

State Street Investment Management (US)

5.56M

1.62%

+702.97K

+14.48%

Jun 30, 2025

Geode Capital Management, L.L.C.

5.99M

1.75%

+864.19K

+16.84%

Jun 30, 2025

Millennium Management LLC

5.38M

1.57%

+1.61M

+42.56%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

2.51%

Virtus LifeSci Biotech Clinical Trials ETF

1.95%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.79%

Tema Oncology ETF

1.66%

ALPS Medical Breakthroughs ETF

0.74%

iShares U.S. Pharmaceuticals ETF

0.46%

iShares Micro-Cap ETF

0.25%

iShares Health Innovation Active ETF

0.24%

Avantis US Small Cap Equity ETF

0.16%

iShares Biotechnology ETF

0.11%

State Street SPDR S&P Pharmaceuticals ETF

占比2.51%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.95%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.79%

Tema Oncology ETF

占比1.66%

ALPS Medical Breakthroughs ETF

占比0.74%

iShares U.S. Pharmaceuticals ETF

占比0.46%

iShares Micro-Cap ETF

占比0.25%

iShares Health Innovation Active ETF

占比0.24%

Avantis US Small Cap Equity ETF

占比0.16%

iShares Biotechnology ETF

占比0.11%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Nuvation Bio Inc的前五大股东是谁？



Nuvation Bio Inc 的前五大股东如下：
Hung (David T)持有股份：60.28M，占总股份比例：17.61%。
Fidelity Management & Research Company LLC持有股份：50.47M，占总股份比例：14.75%。
Decheng Capital LLC持有股份：25.95M，占总股份比例：7.58%。
BlackRock Institutional Trust Company, N.A.持有股份：20.99M，占总股份比例：6.13%。
The Vanguard Group, Inc.持有股份：15.84M，占总股份比例：4.63%。